Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12-02-2020
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
02-04-2019
Seattle Genetics to acquire biotech company for $614m
02-02-2018
Pavel Kapysh / Shutterstock.com
Seattle Genetics has asked the American Arbitration Association (AAA) to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Daiichi Sankyo, American Arbitration Association, Seattle Genetics, trastuzumab deruxtecan, breast cancer, antibody-drug conjugate
